ストックスクリーナーアプリを入手
24.30
1.46%
-0.36
アフターアワーズ：
24.34
0.04
+0.16%
前日終値:
$24.66
開ける：
$24.39
24時間の取引高:
165.67M
Relative Volume:
2.99
時価総額：
$138.16B
収益：
$63.83B
当期純損益:
$10.77B
株価収益率:
12.93
EPS:
1.8799
ネットキャッシュフロー:
$12.44B
1週間 パフォーマンス:
-0.82%
1か月 パフォーマンス:
-11.22%
6か月 パフォーマンス:
+0.41%
1年 パフォーマンス:
-12.46%
1日の値動き範囲:
$24.20
$25.20
1週間の範囲:
$24.15
$25.20
52週間の値動き範囲:
$20.91
$28.00
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.30 | 140.21B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer Q3 Revenue Falls 7% To US$16.7 Billion - BusinessToday Malaysia
Defining The 'Superior' Bid In Pfizer-Novo Legal Battle - Law360
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera - Denver Gazette
Pfizer’s Earnings Call: Strategic Gains Amid Challenges - TipRanks
Pfizer (NYSE:PFE) Trading Down 1.4%Time to Sell? - MarketBeat
PFIZER INC : JP Morgan is Neutral - MarketScreener
Metsera in the middle of Novo, Pfizer bidding war - BioWorld MedTech
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup MetseraWSJ - The Wall Street Journal
Pfizer Weight-Loss $9B Suit: Delaware Court Holds Off Amid High-Stakes Fight Over Metsera - USA Herald
Pfizer ‘Unwavering’ In Pursuit Of Metsera - Citeline News & Insights
Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies - Morningstar
Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... By GuruFocus - Investing.com Canada
Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... - Yahoo Finance
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk - Financial Times
Novo Nordisk Boosts Metsera Bid To $10B After Pfizer Suit - Law360
Pfizer and Novo fatten their bids for weight-loss drugmaker Metsera - Axios
Pfizer Can't Freeze $9B Weight-Loss Drug Fight For Now - Law360
How Pfizer's (PFE) Metsera Legal Fight and Q3 Dip Could Reshape Its Innovation Strategy - Yahoo Finance
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Benzinga
Traders Purchase Large Volume of Pfizer Call Options (NYSE:PFE) - MarketBeat
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Benzinga
Novo Nordisk ups Metsera offer to $10B, outbidding Pfizer - The Business Journals
Pfizer Is Losing Its Fight With Novo Nordisk to Get Back in the Obesity-drug Game - 富途牛牛
Pfizer Narrows Its Outlook And Keeps The Optimism Flowing - Finimize
Novo Nordisk Outbids Pfizer In $10 Billion Metsera Takeover Battle - Finimize
Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera - Barron's
Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle - MarketScreener
Pfizer Q3 Revenue Trends Are Uneven, Cost Cuts Drive EarningsPfizer (NYSE:PFE) - Benzinga
Pfizer Profit Falls Amid Lower Covid-19 Drug Demand - The Wall Street Journal
Pfizer Stock Falls on Third-Quarter Earnings. What Covid-19 Has to Do With It. - Barron's
Pfizer, Novo Boost Bids for Obesity Drugmaker Metsera in Takeover Saga - Bloomberg
Pfizer Q3 2025 slides: EPS beats expectations as company raises guidance - Investing.com
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera - Proactive financial news
Metsera’s Shares Spike Amid Acquisition Proposals from Novo Nordisk and Pfizer - StocksToTrade
Pfizer (PFE) Q3 2025 Earnings Call Transcript - The Globe and Mail
Transcript : Pfizer Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Delaware court won't rule on Pfizer/Novo battle for Metsera today - Seeking Alpha
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo - Reuters
Pfizer : Quarterly Corporate PerformanceThird Quarter 2025 Prepared Remarks - MarketScreener
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up - Yahoo Finance
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer - Houston Chronicle
Pfizer reports strong Q3 earnings, raises full-year profit guidance - Proactive financial news
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools - TradingView
Pfizer’s Q3 Earnings Beat on Top and Bottom Lines - AOL.com
Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025 - MarketScreener
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup - The Wall Street Journal
Pfizer & Novo boost Metsera bids, Hertz stock skyrockets - Yahoo Finance
Novo Nordisk Hikes Metsera Bid to up to $10B in Competition With Rival Pfizer - U.S. News & World Report
Global markets live: Tesla, Amazon, Palantir, Pfizer, Merck… - MarketScreener
Pfizer Inc. 2025 Q3ResultsEarnings Call Presentation (NYSE:PFE) 2025-11-04 - Seeking Alpha
Pfizer says drug pricing agreement with US government has no impact on 2025 guidance - MarketScreener
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.88%
大文字化:
|
ボリューム (24 時間):